Screener
Cytek Biosciences, Inc. CTKB Balance Sheet Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $66.81M-28.4% | $73.85M-2.2% | $31.81M-66.6% | $28.98M-70.6% | $93.28M-42.5% | ||
| $59.19M+4.5% | $49.7M-11.6% | $51.9M-5.7% | $62.51M+3.2% | $56.63M+7.6% | ||
| $52.37M+1.4% | $52.25M+5.6% | $49.79M+9.8% | $48.43M+10.3% | $51.65M+10.4% | ||
| $378.94M-2.5% | $377.93M-1.3% | $379.3M-0.3% | $392M-1.1% | $388.49M-0.4% | ||
| $20.61M+14.2% | $20.8M+13.3% | $20.47M+14.8% | $18.01M+0.3% | $18.05M-2.5% | ||
| $16.69M0.0% | $16.69M-0.1% | $16.69M+0.1% | $16.7M+0.2% | $16.7M+3.2% | ||
| $14.03M-20.6% | $14.87M-20.1% | $15.7M-19.2% | $16.82M-16.4% | $17.68M-13.7% | ||
| $446.15M-9.9% | $446.93M-9.4% | $449.11M-6.9% | $461.54M-7.6% | $494.92M+0.8% | ||
| $4.89M-36.0% | $8.41M+22.7% | $6.74M+7.9% | $6.41M+15.9% | $7.63M+41.6% | ||
| $18.74M+14.9% | $18.06M+8.6% | $30.03M+91.1% | $28.5M+77.1% | $16.32M+10.3% | ||
| $84.95M+13.0% | $84.34M+15.1% | $80.94M+19.6% | $77.8M+15.0% | $75.21M+19.8% | ||
| $99K-84.9% | $246K-68.9% | $386K-58.0% | $525K-50.0% | $655K-47.0% | ||
| $124.79M+7.3% | $124.98M+8.0% | $121.47M+18.0% | $119.8M+15.5% | $116.35M+10.0% | ||
| $131K+2.3% | $130K+2.4% | $1B+781,150% | $129K0.0% | $128K-1.5% | ||
| -$138.86M-141% | -$132.76M-154% | -$120.6M-159% | -$101.74M-189% | -$57.66M-28.6% | ||
| $321.35M-15.1% | $321.95M-14.7% | $327.64M-13.7% | $341.74M-13.6% | $378.57M-1.8% | ||
| $446.15M-9.9% | $446.93M-9.4% | $449.11M-6.9% | $461.54M-7.6% | $494.92M+0.8% |
FAQ
- What are Cytek Biosciences, Inc.'s total assets?
- Cytek Biosciences, Inc. (CTKB) holds $446.1M in total assets, down 9.8% year over year.
- How much debt does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc. carries $16.3M in total debt against $321.4M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc. holds $66.8M in cash and equivalents.
- Can Cytek Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 4.46 — current assets exceed current liabilities.
- Where does Cytek Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
